Unknown

Dataset Information

JAK Inhibitors in Rheumatology: Implications for Paediatric Syndromes?


ABSTRACT:

Purpose of review

Given the recent increase in the profile and use of Janus kinase inhibitors (JAKinibs) in adult patients with rheumatic diseases, we aimed to review the current evidence accruing for use in paediatric rheumatology patients.

Recent findings

Significant advances have been made in the management of rheumatic diseases in the past two decades. The introduction of biologic agents in both adults and children has provided significant improvements to patient outcomes and led to better quality of life. Moreover, responses to similar agents allude to common effector pathways operating across juvenile and adult synovitis especially. However, inefficacy and intolerance of these agents leads to a subset of children with limited treatment options. Since 2012, Janus kinase

SUBMITTER: Kerrigan SA 

PROVIDER: S-EPMC6223710 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature